AngioDynamics Inc. (ANGO) - Q3 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly report on Form 10-Q for AngioDynamics, Inc. for the three and nine months ended February 28, 2026. AngioDynamics is a medical technology company focused on cardiovascular disease and cancer treatment, operating through two segments: Med Tech (Auryon, thrombus management, NanoKnife) and Med Device (Core, Venous, Ports, Oncology). The company is an accelerated filer with no outstanding long-term debt as of the reporting date.
Key Financial Metrics
| Metric | Q3 2026 (3 Months) | Q3 2025 (3 Months) | YTD 2026 (9 Months) | YTD 2025 (9 Months) |
|---|---|---|---|---|
| Net Sales | $78.4 million | $72.0 million | $233.6 million | $212.3 million |
| Gross Margin | 52.9% | 54.0% | 54.9% | 54.4% |
| Operating Loss | ($13.0) million | ($10.0) million | ($29.7) million | ($34.2) million |
| Net Loss | ($8.1) million | ($4.4) million | ($25.3) million | ($27.9) million |
| Diluted Loss Per Share | ($0.19) | ($0.11) | ($0.61) | ($0.68) |
| Cash and Equivalents | $37.8 million | $55.9 million (May 31, 2025) | $37.8 million | $44.8 million (Feb 28, 2025) |
| Operating Cash Flow | ($14.4) million (YTD) | ($28.9) million (YTD) | ($14.4) million | ($28.9) million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8.9% in Q3 and 10.0% YTD compared to the prior year. Growth was driven by the Med Tech segment (+19.0% Q3, +19.1% YTD), specifically Auryon and thrombus management products. Med Device sales grew modestly (+1.2% Q3, +3.2% YTD) due to Core and Venous growth, partially offset by softness in Ports.
- Margin Compression: Q3 gross margin decreased 110 basis points to 52.9%, primarily due to a 320 bps decline in the Med Device segment (44.2%). YTD gross margin improved 50 bps to 54.9%. Headwinds included tariffs ($1.4M Q3 impact), inflation, and production volume variances.
- Restructuring Costs: "Acquisition, restructuring and other items" increased significantly in Q3 to $6.5 million (vs. $3.3 million prior year), driven by $5.2 million in plant closure expenses related to the manufacturing footprint optimization announced in January 2024.
- One-Time Income: Other income included a $5.0 million milestone payment received in Q3 related to divested products, partially offsetting operating losses.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash ($37.8 million) and the $25.0 million secured revolving credit facility (currently undrawn) provide sufficient liquidity for the next 12 months. No debt was outstanding as of February 28, 2026.
- Restructuring Plan: The company continues to execute a restructuring plan to optimize manufacturing. Total estimated costs are $33.4 million to $38.4 million, with $33.2 million recorded to date. Completion is expected by the end of fiscal year 2026.
- Legal Proceedings:
- Patent Litigation: A settlement with C.R. Bard/BD regarding port products involves a $7.0 million lump sum and annual minimum payments of $2.5 million. A Federal Circuit ruling in December 2025 affirmed patent invalidity in favor of AngioDynamics, eliminating contingent payments beyond the minimums.
- Product Liability: The company is defending approximately 347 product liability claims related to port products.
- CEO Transition: Expenses of $0.9 million were recorded in Q3 related to the upcoming retirement of the CEO, announced in January 2026.
- Risks: Key risks include supply chain challenges, inflation, tariffs, foreign currency fluctuations (4.1% of sales in foreign currencies), and the outcome of ongoing litigation.
Investor Verification Checklist
- Restructuring Execution: Verify the timeline and cash impact of the remaining restructuring costs ($5.2M - $5.2M estimated remaining based on total estimate vs. recorded).
- Med Device Margin Recovery: Monitor the Med Device segment's gross margin, which dropped to 44.2% in Q3, to determine if tariff and inflation pressures are stabilizing.
- Port Product Liability Exposure: Review updates on the 347 pending product liability claims and the adequacy of current reserves.
- Cash Burn Rate: Assess the sustainability of the operating cash burn ($14.4M YTD) against the $37.8M cash balance and the $25M credit facility.
- CEO Succession: Confirm the timeline for the CEO transition and any associated retention costs not yet fully recognized.